Cytospire raised £61M in a Series A to advance its cancer drug programs.
- Amount
- $82.6M
- Stage
- Series A
- Announced
- 5 May 2026
- Lead
- 4BIO Capital
- Other investors
- Servier Ventures, Sound Bioventures, British Business Bank, Criteria Bio Ventures, Abingworth, LifeArc Ventures, Modi Ventures, Medical Incubator Japan, Pathway Bioventures
- Use of funds
- Advance pipeline of pan-gamma delta T cell engagers, including lead program CYT X300, into clinical trials
- Checked
- Amount and date checked against the press source